# Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile

> **NCT05516784** · PHASE4 · COMPLETED · sponsor: **Universiti Sains Malaysia** · enrollment: 80 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Ticagrelor

## Key facts

- **NCT ID:** NCT05516784
- **Lead sponsor:** Universiti Sains Malaysia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-08-22
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05516784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05516784, "Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05516784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*